Purpose: The pharmacology, pharmacokinetics, drug interactions, clinical efficacy, adverse effects, monitoring, and dosage and administration of enteric-coated (EC) mycophenolate sodium are reviewed.

Immune thrombocytopenia is a rare autoimmune disorder with associated bleeding risk and fatigue. Recommended first-line treatment for immune thrombocytopenia is high-dose glucocorticoids, but side ...

Please provide your email address to receive an email when new articles are posted on . Mycophenolate mofetil outperformed methotrexate, steroids and other immunosuppressives in diffuse cutaneous SSc ...

Please provide your email address to receive an email when new articles are posted on . Adding mycophenolate mofetil to a glucocorticoid in first-line treatment for immune thrombocytopenia improves ...

Maintenance therapy, often with azathioprine or mycophenolate mofetil, is required to consolidate remission and prevent relapse after the initial control of lupus nephritis. We carried out a 36-month, ...

Mycophenolate mofetil (MMF) has been used successfully as an immunosuppressive medication in transplantation for over a decade. Owing to its efficacy and relatively benign adverse effect profile, its ...

Discover comprehensive details about Mycophenolate Mofetil, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...

BARCELONA, Spain — The JAK inhibitor upadacitinib can effectively treat systemic sclerosis-associated interstitial lung disease (SSc-ILD), according to results from a new clinical trial. Patients ...

A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis. A ...

Credit: Azurity Pharmaceuticals. Myhibbin is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection. Myhibbin is expected to be commercially available in the second ...

In a new analysis of the BLISS LN trial, researchers added Belimumab (Benlysta) to Mycophenolate (MMF), the standard of care treatment for lupus nephritis, (LN, lupus-related kidney disease) and found ...